For OMRC, 2025 marked another significant year of meaningful contributions to the number of novel, FDA-approved medications available to patients in the US affected by chronic inflammatory skin conditions.
OMRC’s dedication to expand and bridge the gap between patients and accessible treatment options is demonstrated through their continuous effort to discover and advance dermatological medicine through research.
Leqselvi (deuruxolitinib) for Alopecia Areata
Leqselvi was approved by the FDA in mid-2024 but only became available to US patients this past year in July 2025. Nicole Friedland, President and CEO of the National Alopecia Areata Foundation (NAAF), said, “The availability of LEQSELVI offers hope to our community, delivering a new, effective treatment option for adults living with severe alopecia areata.” This medicine is a once daily 8 mg tablet, taken with or without food.
Anzupgo (delgocitinib) for Chronic Hand Eczema
Approved on July 23rd, 2025, Anzupgo 2% cream is a topical, non-steroid treatment for adults living with all types of chronic hand eczema (or CHE) whose condition is insufficiently treated with topical corticosteroids. Robert Spurr, Executive Vice President of LEO Pharma, North America emphasized, “As the first and only FDA-approved treatment for CHE, Anzupgo represents an important advance for many patients and further establishes our company’s commitment to bringing innovative treatments to market that address unmet needs in medical dermatology.”
Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria
Rhapsido received FDA approval in September 2025, providing a novel, twice daily oral treatment for people dealing with chronic spontaneous urticaria (or CSU). Dr. Giselle Mosnaim, MD, MS, Clinical Associate Professor at the University of Chicago Pritzker School of Medicine stated, “The approval of remibrutinib is an important development in CSU care… it expands beyond existing injectable treatments and gives patients an oral option that can easily be incorporated into their daily lives.” As the only oral non-antihistamine treatment currently available, Rhapsido improves convenience and accessibility of CSU treatment for patients across the country.
Skyrizi (risankizumab) for Genital and Scalp Psoriasis
While Skyrizi has been available since 2019 for moderate to severe plaque psoriasis, the UnlIMMited trial in 2025 found that it can also benefit patients who have more localized disease. Patients with genital and scalp psoriasis have been underrepresented in traditional psoriasis clinical trials due to enrollment limitations and under-recognition. Dr. James Song, MD, urges clinicians to be proactive with patients since Skyrizi “works well in both of these areas, with high levels of clearance. But the patient reported outcomes, that is what I get really excited about because we saw that it did follow the skin clearance as well.”
Adbry (tralokinumab) for Chronic Hand Eczema
On November 17, 2025, Adbry treatment expanded to include patients with chronic hand eczema (or CHE). While initially approved in 2021 for widespread, moderate to severe atopic dermatitis, new data shows that this injectable medication is effective and improves quality of life for patients with more limited or localized disease as well. Teodora Festini of Global Medical Affairs at LEO Pharma reflects on how “the hands are particularly susceptible to external triggers, which can make disease on the hands especially challenging to manage,” making this new treatment indication particularly exciting and useful for treating clinicians.
https://www.hcplive.com/view/tralokinumab-improves-atopic-dermatitis-hand-involvement-32-weeks